142.50
1.90 (1.35%)
| Penutupan Terdahulu | 140.60 |
| Buka | 140.79 |
| Jumlah Dagangan | 1,410,321 |
| Purata Dagangan (3B) | 1,911,085 |
| Modal Pasaran | 22,600,499,200 |
| Harga / Pendapatan (P/E Ke hadapan) | 30.40 |
| Harga / Jualan (P/S) | 5.22 |
| Harga / Buku (P/B) | 10.73 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Feb 2025 - 10 Feb 2025 |
| Margin Keuntungan | -36.11% |
| Margin Operasi (TTM) | 23.98% |
| EPS Cair (TTM) | -9.97 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 125.84% |
| Nisbah Semasa (MRQ) | 2.43 |
| Aliran Tunai Operasi (OCF TTM) | 697.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 343.12 M |
| Pulangan Atas Aset (ROA TTM) | 2.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -39.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | Illumina, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.10 |
|
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.27% |
| % Dimiliki oleh Institusi | 95.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Guardcap Asset Management Ltd | 30 Sep 2024 | 2,724,818 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 254.00 (RBC Capital, 78.25%) | Beli |
| Median | 165.00 (15.79%) | |
| Rendah | 139.00 (Baird, -2.46%) | Pegang |
| Purata | 170.39 (19.57%) | |
| Jumlah | 6 Beli, 7 Pegang | |
| Harga Purata @ Panggilan | 151.00 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 11 Dec 2024 | 165.00 (15.79%) | Pegang | 147.64 |
| 05 Nov 2024 | 190.00 (33.33%) | Beli | 154.96 | |
| Morgan Stanley | 12 Nov 2024 | 156.00 (9.47%) | Pegang | 147.62 |
| Stephens & Co. | 12 Nov 2024 | 184.00 (29.12%) | Beli | 147.62 |
| Piper Sandler | 11 Nov 2024 | 185.00 (29.82%) | Beli | 151.50 |
| Baird | 06 Nov 2024 | 139.00 (-2.46%) | Pegang | 151.83 |
| Barclays | 05 Nov 2024 | 145.00 (1.75%) | Pegang | 154.96 |
| 15 Oct 2024 | 135.00 (-5.26%) | Pegang | 147.61 | |
| Canaccord Genuity | 05 Nov 2024 | 145.00 (1.75%) | Pegang | 154.96 |
| JP Morgan | 05 Nov 2024 | 140.00 (-1.75%) | Pegang | 154.96 |
| RBC Capital | 05 Nov 2024 | 254.00 (78.25%) | Beli | 154.96 |
| 10 Oct 2024 | 252.00 (76.84%) | Beli | 143.76 | |
| TD Cowen | 05 Nov 2024 | 177.00 (24.21%) | Beli | 154.96 |
| UBS | 05 Nov 2024 | 145.00 (1.75%) | Pegang | 154.96 |
| HSBC | 17 Oct 2024 | 180.00 (26.32%) | Beli | 143.52 |
| Leerink Partners | 17 Oct 2024 | 200.00 (40.35%) | Beli | 143.52 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |